<DOC>
	<DOCNO>NCT00116376</DOCNO>
	<brief_summary>AEE788 orally active , reversible , small-molecule , multi-targeted kinase inhibitor potent inhibitory activity ErbB VEGF receptor family tyrosine kinase . It IC50 le 100 nM p-EGFR , p-ErbB2 , p-KDR ( VEGFR2 ) . This study ass safety , pharmacokinetic/pharmacodynamic ( PK/PD ) profile clinical activity AEE788 recurrent GBM population .</brief_summary>
	<brief_title>Study AEE788 Patients With Recurrent/Relapse Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirm GBM first second recurrence relapse Adequate hematologic , hepatic renal function Age ≥ 18 year Karnofsky performance status score ≥ 70 % Life expectancy ≥ 12 week Peripheral neuropathy &gt; grade 1 Diarrhea &gt; grade 1 Gastrointestinal dysfunction Compromised cardiac function Concurrent severe and/or uncontrolled medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>GBM</keyword>
	<keyword>recurrent/relapse</keyword>
	<keyword>EGFR</keyword>
	<keyword>VEGFR</keyword>
</DOC>